Drugs / LPM6690176
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06240546 | Mar 2024 → Feb 2026 overdue | neoplastic disease or syndrome | Luye Pharma Group Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07391566 | Mar 2026 → Dec 2028 expected | colorectal cancer | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPM6690176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07391566 ↗ |
| Route | Oral | “Administered orally” NCT06240546 ↗ |